In Today trading session, Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP)’s shares saw a move of -0.2902% to close at $0.6529 with trading volume of 204.5 thousand shares. After a look at recent stock performance, shares have traded -12.7805% off of the 50-day moving average and -58.0485% off the 200-day moving average.
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) today announced the appointment of the Honorable Mike Ferguson as a director and Chairman of the Board following the resignation of Ira Greenstein from the Company’s Board of Directors.
Shares of Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP) have been recorded at -83.8790% separated from the 52-week high of $4.0500 and +8.8167% away from the 52-week low of $0.6000. Monitoring the stock price in relation to moving averages as well as highs and lows for the year might assist with evaluating future stock performance.
Wall Street analysts have a consensus target price of $7.5000 on the stock. Target Price predictions might differ vastly from analyst to analyst. This target is applying estimates from analysts polled at Thomson Reuters. Investors may also track a company’s PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. A PEG Ratio near one might be seen as fair value. If a company has a PEG Ratio above one, it may represent that the company is overvalued. A PEG Ratio under one may indicate that the company is undervalued. (NASDAQ:OHRP) has a current PEG Ratio of -0.0100.
“We are honored to have Mike Ferguson join our Board of Directors as our new chairman and believe his experience as a former member of Congress, public policy expert and public health advocate will be invaluable to our Company,” stated Dr. Jason Slakter, CEO. “Mike has a unique understanding of the importance of medical innovation in our society and has been a tireless advocate for public policy reforms to make new medical treatments more available and affordable. We welcome his guidance and counsel. We also wish to thank Ira Greenstein for his many contributions to our Company during his decade of service as the Chairman of our Board of Directors, and wish him all the best in his future endeavors.”
Ohr Pharmaceutical, Inc. is a pharmaceutical company focused on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company’s development pipeline consists of several programs and indications at various stages of development.